Araris Biotech AG Appoints Filippo Mulinacci, Ph.D., MBA as Chief Business Officer
October 12, 2022 10:15 ET
|
Araris Biotech AG
AU ZH, Switzerland, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, is pleased to announce the appointment of...
Araris Biotech Closes $24 Million Financing Round
October 04, 2022 10:15 ET
|
Araris Biotech AG
ZURICH, Switzerland, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Araris Biotech AG (“Araris” or “the Company”), a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today...
Araris Biotech AG to Present at Informa Connect’s Next Generation Protein Therapeutics Summit
September 21, 2022 08:00 ET
|
Araris Biotech AG
ZURICH, Switzerland, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced the company’s chief...
Araris Biotech AG to Present at 13th Annual World ADC San Diego 2022
August 31, 2022 08:00 ET
|
Araris Biotech AG
AU ZH, Switzerland, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced that the company will...
Araris Biotech AG to Present at the H.C. Wainwright Preclinical Cancer Drug Discovery Virtual Conference
June 28, 2022 08:00 ET
|
Araris Biotech AG
ZURICH, Switzerland, June 28, 2022 (GLOBE NEWSWIRE) -- Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced the company will be...
Araris Biotech AG Presents Preclinical Data Highlighting Anti-CD79b ADC Program and Late-Breaking Data on Nectin-4 ADC at the American Association for Cancer Research (AACR) 2022 Annual Meeting
April 08, 2022 13:05 ET
|
Araris Biotech AG
ZURICH, Switzerland, April 08, 2022 (GLOBE NEWSWIRE) -- Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced the company will...
Araris Biotech AG to Present at 12th Annual World ADC London 2022
March 29, 2022 08:00 ET
|
Araris Biotech AG
ZURICH, Switzerland, March 29, 2022 (GLOBE NEWSWIRE) -- Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced that Philipp Probst,...
Araris Biotech AG to Present Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2022
March 09, 2022 08:00 ET
|
Araris Biotech AG
ZURICH, Switzerland, March 09, 2022 (GLOBE NEWSWIRE) -- Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced the company will be...
Araris Biotech AG Expands Scientific Advisory Board with Appointment of Dr. Jeff Sharman and Dr. Clive Stanway
November 11, 2021 03:00 ET
|
Araris Biotech AG
ZURICH, Switzerland, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, announced that the company is expanding...
Araris Biotech AG to Present at 12th Annual World ADC Digital Conference
October 12, 2021 10:00 ET
|
Araris Biotech AG
ZURICH, Switzerland, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, announced that data from its linker...